Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality.

Q2 Medicine
Antibody Therapeutics Pub Date : 2025-01-21 eCollection Date: 2025-04-01 DOI:10.1093/abt/tbaf003
Julianne D Twomey, Sasha George, Baolin Zhang
{"title":"Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality.","authors":"Julianne D Twomey, Sasha George, Baolin Zhang","doi":"10.1093/abt/tbaf003","DOIUrl":null,"url":null,"abstract":"<p><p>The effectiveness of therapeutic antibodies is often associated with their Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. These functions rely on interactions between Fc gamma receptors (FcγRs) on immune cells and the Fc region of antibodies. Genetic variations in these receptors, known as FcγR polymorphisms, can influence therapeutic outcomes by altering receptor expression levels, affinity, and function. This review examines the impact of FcγR polymorphisms on antibody therapy, emphasizing their role in developing and optimizing functional bioassays to assess product quality. Understanding these polymorphisms is essential for refining bioassays, which are crucial for accurately characterizing antibody products and ensuring consistency in manufacturing processes.</p>","PeriodicalId":36655,"journal":{"name":"Antibody Therapeutics","volume":"8 2","pages":"87-98"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959696/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibody Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/abt/tbaf003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The effectiveness of therapeutic antibodies is often associated with their Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. These functions rely on interactions between Fc gamma receptors (FcγRs) on immune cells and the Fc region of antibodies. Genetic variations in these receptors, known as FcγR polymorphisms, can influence therapeutic outcomes by altering receptor expression levels, affinity, and function. This review examines the impact of FcγR polymorphisms on antibody therapy, emphasizing their role in developing and optimizing functional bioassays to assess product quality. Understanding these polymorphisms is essential for refining bioassays, which are crucial for accurately characterizing antibody products and ensuring consistency in manufacturing processes.

抗体治疗中的Fc γ受体多态性:对提高产品质量的生物测定发展的影响。
治疗性抗体的有效性通常与其fc介导的效应功能相关,如抗体依赖性细胞毒性和抗体依赖性细胞吞噬。这些功能依赖于免疫细胞上的Fcγ受体(Fcγ rs)与抗体Fc区之间的相互作用。这些受体的遗传变异,被称为FcγR多态性,可以通过改变受体表达水平、亲和力和功能来影响治疗结果。本文综述了FcγR多态性对抗体治疗的影响,强调了它们在开发和优化功能性生物检测以评估产品质量方面的作用。了解这些多态性对于改进生物测定至关重要,这对于准确表征抗体产品和确保制造过程中的一致性至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antibody Therapeutics
Antibody Therapeutics Medicine-Immunology and Allergy
CiteScore
8.70
自引率
0.00%
发文量
30
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信